Next-generation sequencing reveals genetic heterogeneity in MEFV-negative or heterozygous familial Mediterranean fever: a retrospective study
Comprehensive genetic testing catches more FMF cases missed by standard screening, enabling earlier colchicine treatment and organ-protection monitoring.
In 320 patients clinically diagnosed with FMF who tested negative or heterozygous on standard 16-variant MEFV screening, comprehensive NGS (full MEFV + 18 autoinflammatory genes) identified diagnostically significant variants in 34%, including missed MEFV variants and non-MEFV gene involvement suggesting oligogenic mechanisms. These findings directly support transitioning from targeted panels to comprehensive NGS in FMF-like presentations, with clear implications for colchicine dosing and amyloidosis surveillance.
What the study was
- Study design
- Retrospective diagnostic yield study with NGS
- Population
- Patients clinically diagnosed with FMF who had negative or single heterozygous MEFV result on traditional 16-variant screening (n=320)
- Sample size
- 320
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Expert Review of Clinical Immunology
Why it surfaced
Strong 34% diagnostic uplift from NGS vs standard testing in 320 FMF patients; identifies oligogenic and non-MEFV mechanisms with direct treatment implications (colchicine response, amyloidosis risk); actionable for clinical labs and genetic counselors today.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.